Latest Conference Articles

Melissa Jones, MD, shares insights into recent artificial intelligence (AI) innovations in the realm of sleep studies.

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

The 2024 European Hematology Association (EHA) Congress, convening virtually and in Madrid, Spain, from June 13-16, 2024, will feature practice-changing findings in hematology and oncology, as well as ample networking opportunities and conversations about the future of the field.

Speakers at SLEEP 2024, the annual meeting of The American Academy of Sleep Medicine and Sleep Research Society, share their favorite parts of the conference.

Coverage of a session on antibody drug conjugates from the 2024 American Society of Clinical Oncology Annual Meeting.

Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, explained the phase 3 BOREAS and NOTUS trials demonstrated comparable safety profiles for dupilumab in treating patients with chronic obstructive pulmonary disease (COPD).

During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.

Allison Brager, PhD, neuroscientist, Walter Reed Army Institute of Research, discusses the interplay between physical exercise and circadian rhythms in improving cardiovascular health.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

Slowing the loss of ambulation in patients with Duchenne muscular dystrophy (DMD) may also mitigate worsening disease burden and overall function, according to a pair of posters presented at ISPOR 2024.

A session at the SLEEP 2024 Annual Meeting discussed the various inequities in sleep that persist in individuals who are incarcerated, attend university, or work at hospitals.

Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

A symposium held at the SLEEP 2024 Annual Meeting discussed updates in narcolepsy and idiopathic hypersomnia treatment, specifically in guidelines for treatment and testing in this population.

Use of sodium oxybate and low-sodium oxybate led to meaningful improvements in patients with hypersomnia and narcolepsy regardless of comorbidities.

Chief Health Equity Officer and Senior Vice President Aletha Maybank, MD, MPH, of the American Medical Association (AMA), delivered a powerful plenary session at the CMS Health Equity conference exploring the changes sparked by pivotal moments within the last 5 years.

In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).

Hrayr Attarian, MD, professor of neurology, Northwestern Feinberg School of Medicine, shares findings on sleep inequities that have greatly impacted refugees.

The Alliance A091902 trial is currently investigating paclitaxel with and without nivolumab in patients who are taxane naive and nivolumab plus cabozantinib in taxane-pretreated patients.

Caitlin Kindberg, patient advocate in Nashville, Tennessee, discusses her lived experience as an individual with idiopathic hypersomnia, and how the sleep disorder impacts her day-to-day life.

The relationships among bipolar disorder, sleep, and circadian rhythms were emphasized in a panel held at SLEEP 2024.

This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.

The session held at SLEEP 2024 focused on the challenges of collecting data on sleep and circadian rhythms in adolescents, as well as the difference between home and lab measurements.

An in-depth analysis of minimal residual disease (MRD) negativity results from the PERSEUS trial shows patients whose treatment regimen included subcutaneous daratumumab had responses that deepened over time.

Christopher Depner, PhD, professor of health and kinesiology, University of Utah, shares the challenges of measuring sleep with wearable devices due to nonadherence and the need for metrics like the Sleep Regularity Index.

Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.

The findings can help reduce barriers that delay the onset of recommended palliative care in advanced cancer.

The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.